[
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
[og_img]
https://www.investing.com/news/press-releases/rhythm-pharmaceuticals-to-announce-topline-results-from-pivotal-phase-3-transcend-trial-evaluating-setmelanotide-in-patients-with-acquired-hypothalamic-obesity-93CH-3969537
Investing.com
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
Related articles
